[1]申 丽,李东辉,李 杰,等.纳武单抗在硅纤维沉积性食管鳞癌化疗中的效果及安全性研究[J].陕西医学杂志,2023,52(6):732-736.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.021]
　SHEN Li,LI Donghui,LI Jie,et al.Efficacy and safety of opdivo in chemotherapy for silicon fiber enriched esophageal squamous cell carcinoma[J].,2023,52(6):732-736.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.021]
点击复制

纳武单抗在硅纤维沉积性食管鳞癌化疗中的效果及安全性研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年6期
页码:
732-736
栏目:
药物与临床
出版日期:
2023-06-05

文章信息/Info

Title:
Efficacy and safety of opdivo in chemotherapy for silicon fiber enriched esophageal squamous cell carcinoma
作者:
申 丽; 李东辉; 李 杰; 王艳伟
(邯郸市第一医院纺医院区综合外科,河北 邯郸 056004)
Author(s):
SHEN Li; LI Donghui; LI Jie; WANG Yanwei
(Department of General Surgery,Textile Hospital,Handan First Hospital,Handan 056004,China)
关键词:
硅纤维沉积性食管鳞癌;  纳武单抗;  细胞程序性死亡-配体1;  生存率;  不良反应;  安全性
Keywords:
Silicon fiber enriched esophageal squamous cell carcinoma;  Opdivo;  Programmed cell death 1 ligand 1;  Survival rate;  Adverse reactions;  Safety
分类号:
R 735.1
DOI:
DOI:10.3969/j.issn.1000-7377.2023.06.021
文献标志码:
A
摘要:
目的:探讨细胞程序性死亡-配体1(PD-L1)抑制剂纳武单抗在硅纤维沉积性食管鳞癌化疗中的效果及安全性。方法:选取接受食管癌根治性手术的硅纤维沉积性食管鳞癌患者256例,根据治疗方法的不同分为观察组(132例)和对照组(124例)。两组均给予多西他赛联合奥沙利铂常规化疗方案,同时观察组联合应用纳武单抗治疗。比较两组治疗效果、血清肿瘤标志物、不良反应发生情况、3年无进展生存率及总生存率。结果:观察组总有效率高于对照组(P<0.05)。化疗后,两组血清癌胚抗原(CEA)、糖类抗原199(CA199)、鳞状细胞癌抗原(SCC)水平低于化疗前,且观察组低于对照组(均P<0.05)。无论是化疗1个周期后还是化疗100 d后,观察组不良反应发生率与对照组比较差异无统计学意义(均P>0.05)。观察组3年无进展生存率和总生存率高于对照组(均P<0.05)。结论:硅纤维沉积性食管鳞癌根治术后,在多西他赛联合奥沙利铂方案中增加纳武单抗可以提高疗效和患者生存率,且具有临床安全性。
Abstract:
Objective:To investigate the efficacy and safety of programmed cell death 1 ligand 1(PD-L1)inhibitor opdivo in chemotherapy for silicon fiber enriched esophageal squamous cell carcinoma.Methods:A total of 256 cases of patients with silicon fiber enriched esophageal squamous cell carcinoma who underwent radical surgery were selected and divided into observation group(132 cases)and control group(124 cases)according to different treatment methods.Both groups were given docetaxel combined with oxaliplatin conventional chemotherapy regimen,and the observation group was given opdivo additionally.The therapeutic effect,serum tumor markers,occurrence of adverse reactions,3-year progression-free survival rate and overall survival rate were compared between the two groups.Results:The total effective rate of observation group was higher than that of control group(P<0.05).After chemotherapy,the CEA,CA199 and SCC levels in two groups were lower than those before chemotherapy,and the observation group was lower than control group(all P<0.05).No matter after 1 cycle or 100 d of chemotherapy,there was no significant difference in the incidence of adverse reactions between two groups(all P>0.05).The 3-year progression-free survival rate and overall survival rate in observation group were higher than those in control group(both P<0.05).Conclusion:After radical surgery for silicon fiber enriched esophageal squamous cell carcinoma,adding opdivo to docetaxel combined with oxaliplatin can improve the efficacy and survival rate of patients,and is clinically safe.

参考文献/References:

[1] 王 宁,刘 硕,杨 雷,等.2018全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2019,5(1):87-97.
[2] 王 群,师晓天,李 印,等.中国食管癌临床流行特征及外科治疗概况大数据分析[J].中华肿瘤杂志,2020,42(3):228-233.
[3] 李东辉,刘艳丽,李 杰,等.W1900221-二氧化硅致癌性研究概况[J].中国保健医疗,2019,29(33):41.
[4] 李东辉,刘艳丽,李 杰,等.邯郸食道癌患者食道组织中二氧化硅赋存的研究[J].中国保健营养,2019,29(23):97.
[5] 张 粟,杨 欢,王国清,等.河南省林州市食管鳞癌及癌前病变的影响因素研究[J].中国肿瘤,2020,29(5):327-333.
[6] Pelosof L,Saung MT,Donoghue M,et al.Benefit-risk summary of nivolumab for the treatment of patients with unresectable advanced,recurrent,or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy[J].Oncologist,2021,26(4):318-324.
[7] 蒋琼慧,路泽军,杨 平.肿瘤免疫治疗疗效评价标准——iRECIST解读[J].转化医学杂志,2020,9(1):57-60.
[8] 陈 博,李 涛.清热消滞抗癌方联合放疗对食管癌患者4-羟基壬烯醛、糖类抗原199的影响[J].陕西中医,2022,43(12):1749-1752.
[9] 张广健,李益行,范 坤,等.肠功能恢复汤深部保留灌肠对食管癌术后患者肠功能恢复的疗效研究[J].陕西中医,2022,43(11):1560-1562.
[10] 杨媛媛,孟祥瑞,路 遥,等.免疫检查点抑制剂在食管癌新辅助治疗中的应用进展[J].中国肿瘤临床,2021,48(14):748-753.
[11] 张 博,吴建春,骆莹滨,等.肿瘤免疫治疗及其相关标记物的研究现状与思考[J].中国肿瘤临床,2021,48(5):581-585.
[12] 赵建霞,李东辉,段素芬.二氧化硅所致食管癌高发地区人群的健康宣教[J].中国保健营养,2021,31(16):277-278.
[13] Hastings K,Yu HA,Wei W,et al.EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer[J].Ann Oncol,2019,30(8):1311-1320.
[14] Ghosh S,Nataraj NB,Noronha A,et al.PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR[J].Cell Rep,2021,35(8):109-181.
[15] Liu J,Itchins M,Nagrial A,et al.Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors[J].Lung Cancer,2021,155(48):28-33.
[16] Melosky B,Naso J,Hughesman C,et al.P33.17 incidence of PD-L1 expression at clinically significant cut offs in NSCLC EGFR mutated population compared to wild type[J].J Thorac Oncol,2021,16(3):s412.
[17] 杜文君,陈俊杰,白 晶,等.程序性细胞死亡受体及其配体在肿瘤免疫治疗中的研究进展[J].妇产与遗传:电子版,2020,10(2):24-30.
[18] Sangro B,Melero I,Wadhawan S,et al.Assessment of inflammation biomarkers in relation to clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in checkmate 040[J].J Hepatol,2019,79(13):2675.
[19] 裘飞峰,王凌飞,王 喜,等.抗PD-1/PD-L1单抗治疗进展期非小细胞肺癌的效果及对肿瘤浸润T细胞密度及分布的影响[J].实用癌症杂志,2021,36(7):1120-1122.
[20] 刘 曦,王海东,吴 蔚,等.血清肿瘤坏死因子受体相关蛋白1水平及癌组织癌胚抗原表达与中晚期食管鳞癌化疗效果的相关性[J].中华实用诊断与治疗杂志,2021,35(9):872-875.
[21] 庞芳宁,白 槟,杨 鹏,等.肿瘤标志物CEA、CA199、CA125联合检测对胃癌筛查价值及与TNM分期的关系[J].陕西医学杂志,2020,49(8):1040-1044.
[22] 马小霞,貌彦昀.细胞角蛋白19片段抗原、糖抗原19-9与鳞状细胞癌抗原联合检测在食管癌诊断中的价值研究[J].陕西医学杂志,2021,50(3):359-361,365.
[23] 杜园园,李 鹏,郭旭霞.血清C-反应蛋白联合细胞角蛋白19片段抗原、鳞状上皮细胞癌相关抗原及神经元特异性烯醇化酶检测在食管癌患者中的临床应用[J].中国卫生检验杂志,2020,30(9):1033-1035,1042.

备注/Memo

备注/Memo:
基金项目:河北省科技厅重点研发计划项目(172777150)
更新日期/Last Update: 2023-06-05